{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:26:49Z","timestamp":1772825209505,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejpb.2013.02.001","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T14:42:13Z","timestamp":1361889733000},"page":"511-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"PA","title":["Parenteral formulation of an antileishmanial drug candidate \u2013 Tackling poor solubility, chemical instability, and polymorphism"],"prefix":"10.1016","volume":"85","author":[{"given":"Eva","family":"Kupetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Preu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad","family":"Kunick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2013.02.001_b0005","unstructured":"World Health Organization, <http:\/\/www.who.int\/leishmaniasis\/burden\/magnitude\/burden_magnitude\/en\/index.html> (accessed 2012)."},{"key":"10.1016\/j.ejpb.2013.02.001_b0010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/jm7012166","article-title":"2-(3-Aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype","volume":"51","author":"Reichwald","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2013.02.001_b0015","first-page":"235","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.02.001_b0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.02.001_b0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.addr.2003.10.020","article-title":"High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids","volume":"56","author":"Morissette","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.02.001_b0030","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2013.02.001_b0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.addr.2010.12.007","article-title":"Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology","volume":"63","author":"Merisko-Liversidge","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.02.001_b0040","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1211\/jpp.61.12.0001","article-title":"Review: physical chemistry of solid dispersions","volume":"61","author":"van Janssens","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.02.001_b0045","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.2042-7158.2010.01024.x","article-title":"Lipid nanoparticles for the delivery of poorly water-soluble drugs","volume":"62","author":"Bunjes","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.02.001_b0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-199856050-00001","article-title":"Liposomal drug formulations: rationale for development and what we can expect for the future","volume":"56","author":"Allen","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2013.02.001_b0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2125.1996.03847.x","article-title":"Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation","volume":"41","author":"Soedirman","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.02.001_b0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejps.2005.08.004","article-title":"Transformation of vesicular into cubic nanoparticles by autoclaving of aqueous monoolein\/poloxamer dispersions","volume":"27","author":"W\u00f6rle","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.02.001_b0065","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1023\/B:PHAM.0000045237.46019.6e","article-title":"Supercooled smectic nanoparticles: a potential novel carrier system for poorly water soluble drugs","volume":"21","author":"Kuntsche","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.02.001_b0070","unstructured":"K. Rosenblatt, H. Bunjes, A screening approach to determine the solubilization capacity of lipid nanoparticles for poorly water soluble drugs, poster abstract # 126. In: 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barcelona, 2008, <http:\/\/www.pharmtech.tu-bs.de\/cms\/files\/poster\/2008\/Rosenblatt_Abstract_PBPWorldMeetingBarcelona_2008.pdf>."},{"key":"10.1016\/j.ejpb.2013.02.001_b0075","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.addr.2003.12.005","article-title":"Tocol emulsions for drug solubilization and parenteral delivery","volume":"56","author":"Constantinides","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.02.001_b0080","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2174\/138920008786485155","article-title":"Using measured pKa, logP and solubility to investigate supersaturation and predict BCS class","volume":"9","author":"Box","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejpb.2013.02.001_b0085","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2174\/138920009790820110","article-title":"Predicting aqueous solubility: the role of crystallinity","volume":"10","author":"Chu","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejpb.2013.02.001_b0090","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jps.2600720420","article-title":"Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs","volume":"72","author":"Yamaoka","year":"1983","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.02.001_b0095","unstructured":"C.J. Reichwald, Eine neue Variante der Heck-Reaktion zur Darstellung antileishmanieller Paullone. Dissertation, Braunschweig, 2008."},{"key":"10.1016\/j.ejpb.2013.02.001_b0100","unstructured":"S. Kohfeld, Untersuchungen zur Synthese, biologischen Aktivit\u00e4t und Stabilit\u00e4t von Paullonen und verwandten d-annellierten [1]Benzazepinen. Dissertation, Braunschweig, 2006."},{"key":"10.1016\/j.ejpb.2013.02.001_b0105","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1248\/bpb.20.1266","article-title":"Antitumorigenic activities of chalcones (II). Photo-isomerization of chalcones and the correlation with their biological activities","volume":"20","author":"Iwata","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2013.02.001_b0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0003-2697(91)90148-M","article-title":"Photochemical cis\u2013trans isomerization of furylacryloylpeptides and their different kinetic behavior as substrates for carboxypeptidase Y","volume":"194","author":"Kanstrup","year":"1991","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejpb.2013.02.001_b0115","unstructured":"E. Kupetz, H. Bunjes, Passive loading of lipid nanoparticles with poorly water soluble drugs, poster # 420. In: 25th European Colloid and Interface Society Meeting Berlin, 2011, <http:\/\/www.pharmtech.tu-bs.de\/cms\/files\/poster\/2011\/Kupetz_ECIS_2011.pdf>."},{"key":"10.1016\/j.ejpb.2013.02.001_b0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/8.5.371","article-title":"Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes","volume":"8","author":"New","year":"1981","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1016\/j.ejpb.2013.02.001_b0125","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/0024-3205(82)90098-4","article-title":"Differential uptake of liposomes varying in size and lipid composition by parenchyma and Kupffer cells of mouse liver","volume":"31","author":"Rahman","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2013.02.001_b0130","first-page":"487","article-title":"Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages","volume":"41","author":"Raz","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2013.02.001_b0135","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.02.001_b0140","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-012-0934-1","article-title":"A new nanospray drying method for the preparation of nicergoline pure nanoparticles","volume":"14","author":"Martena","year":"2012","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejpb.2013.02.001_b0145","first-page":"72","article-title":"Zur Polymorphie des Carbamazepins","volume":"32","author":"Kala","year":"1986","journal-title":"Acta Pharm. Technol."},{"key":"10.1016\/j.ejpb.2013.02.001_b0150","first-page":"247","article-title":"Relations between several polymorphic forms and the dihydrate of carbamazepine","volume":"62","author":"Krahn","year":"1987","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.ejpb.2013.02.001_b0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1023\/A:1011052932607","article-title":"Ritonavir: an extraordinary example of conformational polymorphism","volume":"18","author":"Bauer","year":"2001","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T12:01:18Z","timestamp":1539864078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641113000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0939641113000556"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.02.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parenteral formulation of an antileishmanial drug candidate \u2013 Tackling poor solubility, chemical instability, and polymorphism","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}